Clinical Trial Detail

NCT ID NCT03207867
Title A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

pancreatic cancer

renal cell carcinoma

triple-receptor negative breast cancer

head and neck cancer

transitional cell carcinoma

diffuse large B-cell lymphoma

colon cancer

melanoma

Therapies

PBF-509 + PDR001

Age Groups: adult senior

Additional content available in CKB BOOST